BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab

References

• Christensen TD, Spindler KL, Palshof JA, Nielsen DL. Systematic review: brain metastases from colorectal cancer–Incidence and patient characteristics. BMC Cancer. 2016;16:260. doi:10.1186/s12885-016-2290-5
   PubMed Web of Science ®Google Scholar
• Yaeger R, Cowell E, Chou JF, et al. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer. 2015;121(8):1195–1203. doi:10.1002/cncr.29196
   PubMed Web of Science ®Google Scholar
• Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117(20):4623–4632. doi:10.1002/cncr.26086
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Salazar R, Tabernero J. Molecular subtypes and the evolution of treatment decisions in metastatic colorectal cancer. Am. Soc. Clin. Oncol. Educ. Book. 2018;38:231–238. doi:10.1200/EDBK_200929
   PubMedGoogle Scholar
• Śmiech M, Leszczyński P, Kono H, Wardell C, Taniguchi H. Emerging BRAF mutations in cancer progression and their possible effects on transcriptional networks. Genes (Basel). 2020;11(11):1342. doi:10.3390/genes11111342
   PubMed Web of Science ®Google Scholar
• Modest DP, Ricard I, Heinemann V, et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann. Oncol. 2016;27(9):1746–1753. doi:10.1093/annonc/mdw261
   PubMed Web of Science ®Google Scholar
• Tabernero J, Ros J, Élez E. The evolving treatment landscape in BRAF V600E-mutated metastatic colorectal cancer. Am. Soc. Clin. Oncol. Educ. Book. 2022;42:1–10. doi:10.1200/EDBK_349561
   PubMedGoogle Scholar
• Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N. Engl. J. Med. 2019;381(17):1632–1643. doi:10.1056/NEJMoa1908075
   PubMed Web of Science ®Google Scholar
• Mjahed RB, Astaras C, Roth A, Koessler T. Where are we now and where might we be headed in understanding and managing brain metastases in colorectal cancer patients? Curr. Treat. Options Oncol. 2022;23(7):980–1000. doi:10.1007/s11864-022-00982-0
   PubMed Web of Science ®Google Scholar
• Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, Phase II trial. Lancet Oncol. 2017;18(7):863–873. doi:10.1016/S1470-2045(17)30429-1
   PubMed Web of Science ®Google Scholar
• Sakji-Dupré L, Le Rhun E, Templier C, Desmedt E, Blanchet B, Mortier L. Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma. Melanoma Res. 2015;25(4):302–305. doi:10.1097/CMR.0000000000000162
   PubMed Web of Science ®Google Scholar
• Wang J, Gan C, Sparidans RW, et al. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice. Pharmacol. Res. 2018;129:414–423. doi:10.1016/j.phrs.2017.11.006
   PubMed Web of Science ®Google Scholar
• Holbrook K, Lutzky J, Davies MA, et al. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: a case series. Cancer. 2020;126(3):523–530. doi:10.1002/cncr.32547
   PubMed Web of Science ®Google Scholar
• Saberian C, Sperduto P, Davies MA. Targeted therapy strategies for melanoma brain metastasis. Neurooncol. Adv. 2021;3(Suppl. 5):v75–v85. doi:10.1093/noajnl/vdab131
   PubMedGoogle Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 2022;40(2):127–137. doi:10.1200/JCO.21.02229
   PubMed Web of Science ®Google Scholar
• Prasanna D, Elrafei T, Shum E, Strakhan M. More than a headache: a case of cetuximab-induced aseptic meningitis. BMJ Case Rep. 2015;2015:bcr2015209622. doi:10.1136/bcr-2015-209622
   PubMedGoogle Scholar
• Rades D, Nadrowitz R, Buchmann I, et al. Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small-cell lung cancer (NSCLC). Strahlenther Onkol. 2010;186(8):458–462. doi:10.1007/s00066-010-2153-y
   PubMed Web of Science ®Google Scholar
• Kurihara H, Hamada A, Yoshida M, et al. (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res. 2015;5:8. doi:10.1186/s13550-015-0082-6
   PubMed Web of Science ®Google Scholar
• Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs. 2007;18(1):23–28. doi:10.1097/01.cad.0000236313.50833.ee
   PubMed Web of Science ®Google Scholar
• HERCEPTIN for Intravenous Infusion, Pharmaceuticals and medical devices agency. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/450045_4291406D5024_1_11#HDR_Warnings (28 Aug 2023).
   Google Scholar
• ERBITUX Injection 100 mg, Pharmaceuticals and medical devices agency. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/380079_4291415A1021_1_15#HDR_Warnings (28 Aug 2023).
   Google Scholar
• Lampson LA. Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier. MAbs. 2011;3(2):153–160. doi:10.4161/mabs.3.2.14239
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Taieb J, Yaeger R, et al. ANCHOR CRC: Results from a single-arm, phase II study of encorafenib plus binimetinib and cetuximab in previously untreated braf(V600E)-mutant metastatic colorectal cancer. J. Clin. Oncol. 2023;41(14):2628–2637. doi:10.1200/JCO.22.01693
   PubMed Web of Science ®Google Scholar
• Xu T, Wang X, Wang Z, et al. Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors. Ther. Adv. Med. Oncol. 2022;14:17588359221105022.
   Web of Science ®Google Scholar
• Loupakis F, Intini R, Cremolini C, et al. A validated prognostic classifier for (V600E)BRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study. Eur. J. Cancer. 2019;118:121–130. doi:10.1016/j.ejca.2019.06.008
   PubMed Web of Science ®Google Scholar
• Elez E, Ros J, Fernández J, et al. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF(V600E) metastatic colorectal cancer. Nat. Med. 2022;28(10):2162–2170. doi:10.1038/s41591-022-01976-z
   PubMed Web of Science ®Google Scholar
• Kopetz S, Murphy DA, Pu J, et al. Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study. J. Clin. Oncol. 2021;39(Suppl. 15):3513–3513. doi:10.1200/JCO.2021.39.15_suppl.3513
   Google Scholar
• Ros J, Matito J, Villacampa G, et al. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann. Oncol. 2023;34(6):543–552. doi:10.1016/j.annonc.2023.02.016
   PubMed Web of Science ®Google Scholar